Tecvayli Is a Quicker and ‘More Convenient’ Treatment for Myeloma, But Limited Hospital Space Highlights the Need for Outpatient Therapies

Source: Cure Today articles

Tecvayli, which was recently approved for pretreated relapsed/refractory myeloma, is a “much more convenient” treatment option than CAR-T cell therapy, one expert said.

Read More